Crescent Biopharma, Inc.

Crescent Biopharma, Inc.

CBIOยทNASDAQ

$17.95

+5.6%
HealthcareBiotechnology

Crescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.

At a Glance

Live Snapshot
Market Cap$495.05M
EPS-14.7800
P/E Ratio-1.21
Earnings Date07/30/2026
Crescent Biopharma, Inc.

Crescent Biopharma, Inc. Fair Value Envelope

CBIO ยท NASDAQ

Our analysis suggests that CBIO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $17.955, this represents a potential HIDDEN relative to our calculated worth for Crescent Biopharma, Inc..

Intrinsic Value
Current Price: $17.955

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$61.8M
+ Cash & Equivalents$213.2M
Firm Value$151.4M
- Debt$1.6M
Equity Value$149.8M
/ Shares Outstanding13,892,562B
DCF Value$11
OVERVALUED BY 40%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$35.8M
-$17.9M
-$8.9M
-$4.5M
-$2.2M
-$1.1M
-$558.8K
-$279.4K
-$139.7K
-$69.9K
Maintenance CapEx
-$91.9K
-$46.0K
-$23.0K
-$11.5K
-$5.7K
-$2.9K
-$1.4K
-$718
-$359
-$179
Owner Earnings
-$35.9M
-$17.9M
-$9.0M
-$4.5M
-$2.2M
-$1.1M
-$560.3K
-$280.1K
-$140.1K
-$70.0K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$33.2M
-$15.4M
-$7.1M
-$3.3M
-$1.5M
-$706.1K
-$326.9K
-$151.4K
-$70.1K
-$32.4K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.